Search

Welcome to the Division of Chemical & Systems Biology

Barth Research

The major aim of our research is the use of medical biotechnology including antibody technologies, protein engineering & expression, to develop and evaluate knowledge-based innovative recombinant immunodiagnostics and therapeutics. The main characteristics of these novel agents are: a) disease-specific activities, b) reduced unspecific side effects, and c) reduced immunogenicity.

Novel methods for selection of antibodies are developed in close collaboration with Dr. Mehmet K. Tur, Experimental Pathology and Immunotherapy, Institute for Pathology, University Hospital Giessen and Marburg, Germany.

Novel fusion proteins will be designed using advanced supercomputing tools to model dynamic interactions of proteins, in close collaboration with Prof. Dr. Paolo Carloni, Institute for Advanced Simulation, Forschungszentrum Jülich, Germany. Recombinant fusion proteins are mainly expressed in bacterial or mammalian cells and subsequently characterized in experimental settings, both in vitro on cell lines or primary material of patients and in vivo intransgenic/tumor-bearing mouse models.